Mitchell Toby Victor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mitchell Toby Victor has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Theresa Guo
Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA
5 shared publications - Anna M. Dornisch
Department of Radiation Medicine and Applied Sciences, University of California, San Diego, CA 92037, USA
1 shared publication Brent S. Rose
Department of Radiation Medicine and Applied Sciences University of California San Diego Health La Jolla California USA
1 shared publication- Farhoud Faraji
Department of Otolaryngology—Head and Neck Surgery University of California San Diego La Jolla California USA
1 shared publication Hannah Carter
Moores Cancer Center UC San Diego Health La Jolla California USA
1 shared publication- Jennifer Chang
Department of Radiology, University of California, San Diego, CA 92037, USA
1 shared publication
Latest Publications
- Open Access
- 6 October 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (10) , 602
Induction Systemic Therapy Followed by Response-Adapted Consolidative Radiation in Locally Advanced Non-Melanoma Skin Cancer: A Retrospective Case Series
Background: There exists an unmet clinical need to define definitive management strategies for patients with locally advanced non-melanoma skin cancers (NMSC), particularly if not amenable to surgical resection. Methods: We retrospectively reviewed a case series of locally advanced unresectable NMSC treated with induction systemic treatment followed by response-adapted consolidative radiation. Results: We identified 15 patients who met study criteria, including seven with basal cell carcinoma (BCC), six with cutaneous squamous cell carcinoma (CSCC), and two with Merkel cell carcinoma (MCC). Clinical complete response (CR) by physical examination was observed in all 15 patients. No locoregional or distant recurrences were observed in any histologic subtype after completion of radiation (median follow-up from completion of radiation: 18.1 months BCC, 22.5 months CSCC, 22.7 months MCC). The median duration of observed response (DOOR), measured from first clinical response was 26.9 months (26.2 BCC, 29.4 CSCC, 27.1 MCC). Radiation treatment volumes were response-adapted with median gross tumor volume reduction of 55.3% (15.3%–100%). Median treatment-free response was 20.5 months. No unexpected systemic therapy related toxicities were identified. Conclusions: In this single-institution retrospective case series, induction systemic therapy followed by response-adapted consolidative radiation was feasible and associated with durable disease control in selected patients with locally advanced unresectable NMSC.
- 6 October 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (10) , 602
Open AccessInduction Systemic Therapy Followed by Response-Adapted Consolidative Radiation in Locally Advanced Non-Melanoma Skin Cancer: A Retrospective Case Series
Background: There exists an unmet clinical need to define definitive management strategies for patients with locally advanced non-melanoma skin cancers (NMSC), particularly if not amenable to surgical resection. Methods: We retrospectively reviewed a case series of locally advanced unresectable NMSC treated with induction systemic treatment followed by response-adapted consolidative radiation. Results: We identified 15 patients who met study criteria, including seven with basal cell carcinoma (BCC), six with cutaneous squamous cell carcinoma (CSCC), and two with Merkel cell carcinoma (MCC). Clinical complete response (CR) by physical examination was observed in all 15 patients. No locoregional or distant recurrences were observed in any histologic subtype after completion of radiation (median follow-up from completion of radiation: 18.1 months BCC, 22.5 months CSCC, 22.7 months MCC). The median duration of observed response (DOOR), measured from first clinical response was 26.9 months (26.2 BCC, 29.4 CSCC, 27.1 MCC). Radiation treatment volumes were response-adapted with median gross tumor volume reduction of 55.3% (15.3%–100%). Median treatment-free response was 20.5 months. No unexpected systemic therapy related toxicities were identified. Conclusions: In this single-institution retrospective case series, induction systemic therapy followed by response-adapted consolidative radiation was feasible and associated with durable disease control in selected patients with locally advanced unresectable NMSC.
- 4 August 2025
- Published by Wiley in Head & Neck
- Vol. 48 (1) , 45-55
Aberrant Splicing Burden Predicts Immune Infiltration and Prognosis in Head and Neck Squamous Cell Carcinomas
Background: The role of alternative splicing events (ASEs) in immune evasion and prognosis in head and neck squamous cell carcinoma (HNSC) is not well characterized. Methods: Using The Cancer Genome Atlas data, we identified ASEs (using our novel algorithm OutSplice) and characterized associations between splice burden, immune infiltration (quantified by xCell) and prognosis with multivariable logistic regression and survival models. Results: HSNC tumors with low splice burden and high immune infiltration had significantly better prognosis than tumors with high splice burden and low immune infiltration when controlling for age, pathologic stage, HPV status, and tumor mutational burden (hazard ratio = 0.61). High splice burden predicted decreased immune infiltration in HNSC, which was validated in five other cancer types and supported by murine models of oral squamous cell carcinoma. Conclusions: High splicing burden, as defined by OutSplice, is a novel biomarker to predict poor both immune infiltration and prognosis in HNSC.
- 4 August 2025
- Published by Wiley in Head & Neck
- Vol. 48 (1) , 45-55
Aberrant Splicing Burden Predicts Immune Infiltration and Prognosis in Head and Neck Squamous Cell Carcinomas
Background: The role of alternative splicing events (ASEs) in immune evasion and prognosis in head and neck squamous cell carcinoma (HNSC) is not well characterized. Methods: Using The Cancer Genome Atlas data, we identified ASEs (using our novel algorithm OutSplice) and characterized associations between splice burden, immune infiltration (quantified by xCell) and prognosis with multivariable logistic regression and survival models. Results: HSNC tumors with low splice burden and high immune infiltration had significantly better prognosis than tumors with high splice burden and low immune infiltration when controlling for age, pathologic stage, HPV status, and tumor mutational burden (hazard ratio = 0.61). High splice burden predicted decreased immune infiltration in HNSC, which was validated in five other cancer types and supported by murine models of oral squamous cell carcinoma. Conclusions: High splicing burden, as defined by OutSplice, is a novel biomarker to predict poor both immune infiltration and prognosis in HNSC.
- Open Access
- 6 August 2024
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 9 (4) , e1317
Factors associated with total laryngectomy following organ‐preserving treatment of laryngeal SCC
Objective(s): A subset of laryngeal squamous cell carcinoma (LSCC) patients undergoing larynx preserving treatment ultimately require total laryngectomy (TL) for oncologic or functional reasons. This study aims to identify TL risk factors in these patients.Methods: Retrospective cohort study using Veterans Affairs (VA) database. T1–T4 LSCC cases treated with primary radiotherapy (XRT) or chemoradiotherapy (CRT) were assessed for TL and recurrence. Binary logistic and Cox regression and Kaplan–Meier analyses were implemented.Results: Of 5390 cases, 863 (16.0%) underwent TL. On multivariable analysis, age (adjusted odds ratio: 0.97 [0.96–0.98]; p < .001) and N3 disease (0.42 [0.18–1.00]; p = .050) were associated with reduced risk of TL, whereas current alcohol use (1.22 [1.04–1.43]; p = .015) and >T1 disease (T2, 1.76 [1.44–2.17]; p < .001; T3, 2.06 [1.58–2.68]; p < .001; T4, 1.79 [1.26–2.53]; p = .001) were associated with increased risk of TL. However, N2 (adjusted hazard ratio: 1.30 [1.10–1.55]; p = .003) and N3 (2.02 [1.25–3.26]; p = .004) disease were associated with an increased risk for local recurrence. Compared to XRT, treatment with CRT was associated with reduced risk for local recurrence after adjusting for other factors (0.84 [0.70–0.99]; p = .044). Those who do not receive TL following local recurrence have poorer disease‐specific survival (log‐rank, p < .001). In patients without local recurrence, N2 disease was associated with a fourfold increase in risk of TL (4.24 [1.83–9.82]; p < .001).Conclusion: Advanced nodal stage was associated with reduced rates of salvage TL in the setting of local recurrence, and subsequent worse prognosis after recurrence. Conversely, advanced nodal stage may increase the risk for functional salvage TL in patients without recurrence.Level of Evidence: Level 3.
- 6 August 2024
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 9 (4) , e1317
Open AccessFactors associated with total laryngectomy following organ‐preserving treatment of laryngeal SCC
Objective(s): A subset of laryngeal squamous cell carcinoma (LSCC) patients undergoing larynx preserving treatment ultimately require total laryngectomy (TL) for oncologic or functional reasons. This study aims to identify TL risk factors in these patients.Methods: Retrospective cohort study using Veterans Affairs (VA) database. T1–T4 LSCC cases treated with primary radiotherapy (XRT) or chemoradiotherapy (CRT) were assessed for TL and recurrence. Binary logistic and Cox regression and Kaplan–Meier analyses were implemented.Results: Of 5390 cases, 863 (16.0%) underwent TL. On multivariable analysis, age (adjusted odds ratio: 0.97 [0.96–0.98]; p < .001) and N3 disease (0.42 [0.18–1.00]; p = .050) were associated with reduced risk of TL, whereas current alcohol use (1.22 [1.04–1.43]; p = .015) and >T1 disease (T2, 1.76 [1.44–2.17]; p < .001; T3, 2.06 [1.58–2.68]; p < .001; T4, 1.79 [1.26–2.53]; p = .001) were associated with increased risk of TL. However, N2 (adjusted hazard ratio: 1.30 [1.10–1.55]; p = .003) and N3 (2.02 [1.25–3.26]; p = .004) disease were associated with an increased risk for local recurrence. Compared to XRT, treatment with CRT was associated with reduced risk for local recurrence after adjusting for other factors (0.84 [0.70–0.99]; p = .044). Those who do not receive TL following local recurrence have poorer disease‐specific survival (log‐rank, p < .001). In patients without local recurrence, N2 disease was associated with a fourfold increase in risk of TL (4.24 [1.83–9.82]; p < .001).Conclusion: Advanced nodal stage was associated with reduced rates of salvage TL in the setting of local recurrence, and subsequent worse prognosis after recurrence. Conversely, advanced nodal stage may increase the risk for functional salvage TL in patients without recurrence.Level of Evidence: Level 3.
- Open Access
- 15 September 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (18_Supplem) , PO-075-075
Abstract PO-075: Immunosuppression allows for proliferation of alternative splicing events in a murine model of tobacco-associated oral cavity squamous cell carcinoma
Background: Non-canonical alternative splicing events have been demonstrated to occur in head and neck squamous cell carcinoma, and result in functionally active aberrant isoforms that contribute to carcinogenesis. Our preliminary data also demonstrates that high splicing burden is associated with higher recurrence rates in oral cancer as well as relative immunosuppression. These splicing events are hypothesized to generate immunogenic neoantigens given non-self sequences that are generated from these novel isoforms. However, the role of the immune system in regulating the proliferation of aberrant splicing is not well understood. Therefore, we evaluated splicing alteration in the setting of immunosuppression in a murine model of oral cancer. Study Design: An established murine cell line with genetic signature resembling human tobacco-associated oral cavity SCC (4MOSC1) was injected into the oral tongue of wild type (C57/Blk6) and immunocompromised (SCID) mice. At takedown, specimens were collected for bulk RNA sequencing (RNASeq). Fastq files were aligned to mm39 using STAR v.2.7.1a. Splicing analysis was performed using OutSplice. Somatic variants in tumor samples were determined from RNASeq data using the GATK v4.4.0 tool Mutect2. Mutational burden was estimated using the number of single nucleotide variants (SNVs) called in each sample (CountVariants, GATK). Trinity v2.12.0 and NetMHCPan v4.1 were used to define PHBR scores to predict MHC binding affinity of neopeptides. Results: Seven of ten mice had measurable tumor by day 5, for an engraftment rate of 70% (3/5 C57/Blk6; 4/5 SCID). At day 15, tumors in wild type mice had a mean volume of 14.7mm3 compared to 28.9mm3 in SCID mice (one-sided p=0.132). Sequencing analysis demonstrated that splicing burden was higher in tumors developed in SCID mice compared to Blk6 mice (mean 475.25 vs 381.67, p=0.022). The mean number of SNVs were 144.2 mt/mb in SCID mice compared to 81.2 mt/mb in Blk6 mice (p=0.044). Amongst predicted splice derived neopeptides, those in SCID tumors had lower PHBR scores versus wild type tumors (median: 3.13 vs 4.23, p<0.001), correlating with higher predicted MHC binding affinity. However, amongst very strong binders (PHBR score ≤0.5), there was no difference in PHBR score between groups (0.30 vs 0.22, p=0.97). Conclusion: As expected, immunosuppression allowed for increased growth of tumors in the murine oral cancer model. We show that immunosuppression allows for the proliferation of both alternative splicing events and mutations. These preliminary data demonstrate that the immune system may play a role in regulating aberrant splicing events in oral cancer. Aberrant splice derived peptides which stimulate the immune system may be more likely to develop in an immunosuppressed setting. Citation Format: Mitchell Victor, Sophie Jang, Joseph Bendik, Silvio Gutkind, Theresa Guo. Immunosuppression allows for proliferation of alternative splicing events in a murine model of tobacco-associated oral cavity squamous cell carcinoma [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-075.
- 15 September 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (18_Supplem) , PO-075-075
Open AccessAbstract PO-075: Immunosuppression allows for proliferation of alternative splicing events in a murine model of tobacco-associated oral cavity squamous cell carcinoma
Background: Non-canonical alternative splicing events have been demonstrated to occur in head and neck squamous cell carcinoma, and result in functionally active aberrant isoforms that contribute to carcinogenesis. Our preliminary data also demonstrates that high splicing burden is associated with higher recurrence rates in oral cancer as well as relative immunosuppression. These splicing events are hypothesized to generate immunogenic neoantigens given non-self sequences that are generated from these novel isoforms. However, the role of the immune system in regulating the proliferation of aberrant splicing is not well understood. Therefore, we evaluated splicing alteration in the setting of immunosuppression in a murine model of oral cancer. Study Design: An established murine cell line with genetic signature resembling human tobacco-associated oral cavity SCC (4MOSC1) was injected into the oral tongue of wild type (C57/Blk6) and immunocompromised (SCID) mice. At takedown, specimens were collected for bulk RNA sequencing (RNASeq). Fastq files were aligned to mm39 using STAR v.2.7.1a. Splicing analysis was performed using OutSplice. Somatic variants in tumor samples were determined from RNASeq data using the GATK v4.4.0 tool Mutect2. Mutational burden was estimated using the number of single nucleotide variants (SNVs) called in each sample (CountVariants, GATK). Trinity v2.12.0 and NetMHCPan v4.1 were used to define PHBR scores to predict MHC binding affinity of neopeptides. Results: Seven of ten mice had measurable tumor by day 5, for an engraftment rate of 70% (3/5 C57/Blk6; 4/5 SCID). At day 15, tumors in wild type mice had a mean volume of 14.7mm3 compared to 28.9mm3 in SCID mice (one-sided p=0.132). Sequencing analysis demonstrated that splicing burden was higher in tumors developed in SCID mice compared to Blk6 mice (mean 475.25 vs 381.67, p=0.022). The mean number of SNVs were 144.2 mt/mb in SCID mice compared to 81.2 mt/mb in Blk6 mice (p=0.044). Amongst predicted splice derived neopeptides, those in SCID tumors had lower PHBR scores versus wild type tumors (median: 3.13 vs 4.23, p<0.001), correlating with higher predicted MHC binding affinity. However, amongst very strong binders (PHBR score ≤0.5), there was no difference in PHBR score between groups (0.30 vs 0.22, p=0.97). Conclusion: As expected, immunosuppression allowed for increased growth of tumors in the murine oral cancer model. We show that immunosuppression allows for the proliferation of both alternative splicing events and mutations. These preliminary data demonstrate that the immune system may play a role in regulating aberrant splicing events in oral cancer. Aberrant splice derived peptides which stimulate the immune system may be more likely to develop in an immunosuppressed setting. Citation Format: Mitchell Victor, Sophie Jang, Joseph Bendik, Silvio Gutkind, Theresa Guo. Immunosuppression allows for proliferation of alternative splicing events in a murine model of tobacco-associated oral cavity squamous cell carcinoma [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-075.
- 25 August 2023
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 170 (1) , 132-140
Insurance Status is Associated With Recurrence in Cutaneous Head and Neck Squamous Cell Carcinoma
Objective: To identify socioeconomic factors influencing the presentation and outcomes of cutaneous head and neck squamous cell carcinoma (cHNSCC).Study Design: Retrospective cohort study.Setting: Tertiary academic medical center with comprehensive cancer center.Methods: Patients treated for cHNSCC at a single institution between 2008 and 2022 were included. Demographic, socioeconomic data and disease characteristics were obtained from medical record abstraction. Outcome measures included tumor stage, number of distinct primaries, recurrence, and disease‐related death. χ2 and Mann‐Whitney tests were implemented to evaluate clinicopathologic distributions across disease stages. Survival analyses were performed using Cox regression and Kaplan‐Meier analysis.Results: A total of 346 patients met the inclusion criteria. The median age at presentation and length of follow‐up was 70.8 and 3.1 years, respectively. The majority of the cohort was white, male, and English‐speaking. 13.3% of patients were underinsured and 27.5% were immunosuppressed. Patients who presented with advanced disease were more likely to be underinsured (21.7% vs 9.6%, P = .006) and have a history of homelessness (8.5% vs 2.1%, P = .014). Immunosuppressed patients were more likely to be underinsured (P = .009). Insurance status (1.97 [1.06‐3.66], P = .032) and immune status (2.35 [1.30‐4.26], P = .005) were independently associated with worse recurrence‐free survival.Conclusion: Socioeconomic factors that influence access to care, such as insurance status, are associated with cHNSCC disease stage and disease recurrence. These factors may impose barriers that delay diagnosis and treatment. This may result in worse disease‐related outcomes and greater treatment‐associated morbidity for certain patients.
- 25 August 2023
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 170 (1) , 132-140
Insurance Status is Associated With Recurrence in Cutaneous Head and Neck Squamous Cell Carcinoma
Objective: To identify socioeconomic factors influencing the presentation and outcomes of cutaneous head and neck squamous cell carcinoma (cHNSCC).Study Design: Retrospective cohort study.Setting: Tertiary academic medical center with comprehensive cancer center.Methods: Patients treated for cHNSCC at a single institution between 2008 and 2022 were included. Demographic, socioeconomic data and disease characteristics were obtained from medical record abstraction. Outcome measures included tumor stage, number of distinct primaries, recurrence, and disease‐related death. χ2 and Mann‐Whitney tests were implemented to evaluate clinicopathologic distributions across disease stages. Survival analyses were performed using Cox regression and Kaplan‐Meier analysis.Results: A total of 346 patients met the inclusion criteria. The median age at presentation and length of follow‐up was 70.8 and 3.1 years, respectively. The majority of the cohort was white, male, and English‐speaking. 13.3% of patients were underinsured and 27.5% were immunosuppressed. Patients who presented with advanced disease were more likely to be underinsured (21.7% vs 9.6%, P = .006) and have a history of homelessness (8.5% vs 2.1%, P = .014). Immunosuppressed patients were more likely to be underinsured (P = .009). Insurance status (1.97 [1.06‐3.66], P = .032) and immune status (2.35 [1.30‐4.26], P = .005) were independently associated with worse recurrence‐free survival.Conclusion: Socioeconomic factors that influence access to care, such as insurance status, are associated with cHNSCC disease stage and disease recurrence. These factors may impose barriers that delay diagnosis and treatment. This may result in worse disease‐related outcomes and greater treatment‐associated morbidity for certain patients.